Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical impact of pharmacokinetic monitoring of antibiotics in critically ill patients
2023-504480-17-00Phase 4Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jul 2023
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of daptomycin, meropenem, cefepime, linezolid and piperacillin in bacterial disease (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Days of admission to ICU, Days of hospital admission and 7 more. Planned start Jul 2023; status: authorised.
02
Drugs
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2023-504480-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504480-17-00.